# Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain

> **NCT05196919** · PHASE2 · COMPLETED · sponsor: **Xalud Therapeutics, Inc.** · enrollment: 75 (actual)

## Conditions studied

- Facet Joint Pain
- Back Pain
- Inflammation

## Interventions

- **BIOLOGICAL:** XT-150
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05196919
- **Lead sponsor:** Xalud Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-24
- **Primary completion:** 2023-09-20
- **Final completion:** 2023-09-20
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05196919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05196919, "Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05196919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*